Scholarlink

Background <p>Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy with different molecular and genetic alterations. CD155 is expressed on myeloid cells and serves as a recognition molecule for natural killer (NK) cells to induce cytotoxicity. This study aimed to assess the prognostic and predictive value of CD155 in patients with AML.</p> Methods <p>We studied the expression of CD155 via flow cytometry in 93 AML patients at initial diagnosis at the Medical Oncology Department, South Egypt Cancer Institute (SECI), Egypt.</p> Results <p>Flow cytometry revealed that a mean fluorescence intensity ratio (MFIR) ≥2.68 was associated with high CD155 expression. This criterion was met in 62 patients (66.7%). High expression was associated with a worse composite complete remission (CRc) rate than low expression (29.0 vs. 54.8%; <i>P</i> = 0.015). High CD155 expression had significantly shorter relapse-free survival (RFS), with a median of 1.68 (95% CI 0.92–2.43) months (<i>P</i> = 0.015), and overall survival (OS), with a median of 1.68 (95% CI 0.74–2.88) months (<i>P</i> = 0.041).</p> Conclusions <p>High expression of CD155 in adult patients with AML is associated with a lower CRc, shorter RFS, and OS. It could be included within the predictive and prognostic panels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CD155 as a prognostic and predictive biomarker in acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月24日

查看全文
  • Ashraf Zeidan Abdalla,
  • Salah Mabrouk Khallaf,
  • Asmaa Mohammed Zahran,
  • Nehal Adel Rayan,
  • Ahmed Refaat Abd Elzaher

摘要

Background

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy with different molecular and genetic alterations. CD155 is expressed on myeloid cells and serves as a recognition molecule for natural killer (NK) cells to induce cytotoxicity. This study aimed to assess the prognostic and predictive value of CD155 in patients with AML.

Methods

We studied the expression of CD155 via flow cytometry in 93 AML patients at initial diagnosis at the Medical Oncology Department, South Egypt Cancer Institute (SECI), Egypt.

Results

Flow cytometry revealed that a mean fluorescence intensity ratio (MFIR) ≥2.68 was associated with high CD155 expression. This criterion was met in 62 patients (66.7%). High expression was associated with a worse composite complete remission (CRc) rate than low expression (29.0 vs. 54.8%; P = 0.015). High CD155 expression had significantly shorter relapse-free survival (RFS), with a median of 1.68 (95% CI 0.92–2.43) months (P = 0.015), and overall survival (OS), with a median of 1.68 (95% CI 0.74–2.88) months (P = 0.041).

Conclusions

High expression of CD155 in adult patients with AML is associated with a lower CRc, shorter RFS, and OS. It could be included within the predictive and prognostic panels.